Biocon biosimilar plant criticized again by the FDA | Fierce Pharma
Biocon Academy - Biocon
Biocon logo in transparent PNG format
Cash-and-stock deal: Biocon Biologics acquires Viatris for $3.33 billion | The Financial Express
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Biocon Biologics appoints Susheel Umesh as Chief Commercial Officer for emerging markets | Deccan Herald
Meet Biocon Biologics: A 2021 Facility of the Year Honorable Mention Award Winner | Pharmaceutical Engineering
Biocon subsidiary acquires Viatris pharma for $3 billion | Mint
Biocon announces merger of its arm with Serum Institute subsidiary - BusinessToday
Biocon - Crunchbase Company Profile & Funding
Biocon - Wikipedia
Biocon Biologics (@BioconBiologics) / Twitter
Biocon Biologics enters licensing agreement with Yoshindo of Japan - The Hindu BusinessLine
Biocon - 72 new faces joined us in February. Many... | Facebook
Biocon Campus - Biocon
Biocon Campus - Biocon
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs - Biocon
India's Biocon Biologics to receive $150m from Goldman Sachs - Nikkei Asia
Covid has created an 'ecosystem' of innovation in India, says Biocon chief Kiran Mazumdar-Shaw | Mint
Biocon's pre-tax profit rises 9% to Rs 315 crore in Oct-Dec quarter | Business Standard News
Syngene International: Biocon sells 5.4% stake in arm Syngene International - The Economic Times
Biocon sells 5.4% stake in its research arm Syngene International - Hindustan Times
Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Biocon Q4 results show Consolidated revenue up by 21% - The Statesman
